{"id":"platinum","rwe":[],"_fda":{"id":"1f92ea6e-90d0-427d-a07f-ac1a41600d5a","set_id":"12786efd-df42-4321-bfdf-88f542d387bb","openfda":{"nui":["N0000185371","N0000175629","N0000184306","M0000728","M0006342","M0016962","N0000185508"],"upc":["0363113701777"],"unii":["1TH8Q20J0U","O3B55K4YKI","535G2ABX9M","V1V998DC17","79Y1949PYO","C21158IIRK","RGL5YE86CZ","9679TC07X4","324Y4038G2","7OV03QG267","11E6VI8VEG","49DFR088MY","ETJ7Z6XBU4","3M4G523W1G","91D9GV0Z28","J41CSQ7QDS"],"route":["ORAL"],"spl_id":["1f92ea6e-90d0-427d-a07f-ac1a41600d5a"],"brand_name":["Dentastat"],"spl_set_id":["12786efd-df42-4321-bfdf-88f542d387bb"],"package_ndc":["44911-0661-1"],"product_ndc":["44911-0661"],"generic_name":["ALLIUM SATIVUM, BERBERIS VULGARIS, FUCUS VESICULOSUS, PHYTOLACCA DECANDRA, ARGENTUM METALLICUM, AURUM METALLICUM, CALCAREA FLUORICA, CALCAREA PHOSPHORICA, HEKLA LAVA, HYDROFLUORICUM ACIDUM, IODIUM, MERCURIUS SOLUBILIS, NICCOLUM METALLICUM, SILICEA, ZINCUM METALLICUM, PLATINUM METALLICUM"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Dietary Proteins [CS]","Plant Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]"],"substance_name":["BERBERIS VULGARIS ROOT BARK","CALCIUM FLUORIDE","FUCUS VESICULOSUS","GARLIC","GOLD","HEKLA LAVA","HYDROFLUORIC ACID","IODINE","MERCURIUS SOLUBILIS","NICKEL","PHYTOLACCA AMERICANA ROOT","PLATINUM","SILICON DIOXIDE","SILVER","TRIBASIC CALCIUM PHOSPHATE","ZINC"],"pharm_class_epc":["Non-Standardized Food Allergenic Extract [EPC]","Standardized Chemical Allergen [EPC]"],"manufacturer_name":["Energique, Inc."],"is_original_packager":[true]},"purpose":["PURPOSES: Argentum Metallicum – bruised pains**, Aurum Metallicum – foul breath**, Calcarea Fluorica – sensitive teeth**, Calcarea Phosphorica – bitter taste**, Hekla Lava – toothache**, Hydrofluoricum Acidum – sore mouth**, Iodium – sweetish taste**, Mercurius Solubilis – metallic taste**, Niccolum Metallicum – stiff tongue**, Phytolacca Decandra – lymphatic congestion**, Platinum Metallicum – tongue pain**, Silicea - dry mouth**, Zincum Metallicum – bleeding gums**, Allium Sativum – swollen gums**, Berberis Vulgaris – thick saliva**, Fucus Vesiculosus – neck swelling**. **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"version":"2","warnings":["WARNINGS: Stop use and ask a doctor if symptoms persist for more than 7 days. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. DO NOT USE IF TAMPER EVIDENT SEAL IS BROKEN OR MISSING. Store in a cool, dry place."],"questions":["QUESTIONS: Dist. by Energique, Inc. 201 Apple Blvd. Woodbine, IA 51579 800.869.8078"],"effective_time":"20241024","active_ingredient":["ACTIVE INGREDIENTS: (in each drop) Argentum Metallicum 12X 7.67%, Aurum Metallicum 12X 7.67%, Calcarea Fluorica 12X 7.67%, Calcarea Phosphorica 12X 7.67%, Hekla Lava 12X 7.67%, Hydrofluoricum Acidum 12X 7.67%, Iodium 12X 7.67%, Mercurius Solubilis 12X 7.67%, Niccolum Metallicum 12X 7.67%, Phytolacca Decandra 6X 7.67%, Platinum Metallicum 16X 7.67%, Silicea 12X 7.67%, Zincum Metallicum 12X 7.67%, Allium Sativum 3X 0.10%, Berberis Vulgaris 3X 0.10%, Fucus Vesiculosus 3X 0.10%."],"inactive_ingredient":["INACTIVE INGREDIENTS: Demineralized water, 20% Ethanol."],"indications_and_usage":["USES: May temporarily relieve symptoms associated with dental procedures, such as: pain and minor swelling in the mouth or on the gums.** ** Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"dosage_and_administration":["DIRECTIONS: • Adults and children 5 to 10 drops orally, 3 times daily or as otherwise directed by a health care professional. • Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["Dentastat Allium Sativum, Berberis Vulgaris, Fucus Vesiculosus, Phytolacca Decandra, Argentum Metallicum, Aurum Metallicum, Calcarea Fluorica, Calcarea Phosphorica, Hekla Lava, Hydrofluoricum Acidum, Iodium, Mercurius Solubilis, Niccolum Metallicum, Silicea, Zincum Metallicum, Platinum Metallicum GARLIC GARLIC BERBERIS VULGARIS ROOT BARK BERBERIS VULGARIS ROOT BARK FUCUS VESICULOSUS FUCUS VESICULOSUS PHYTOLACCA AMERICANA ROOT PHYTOLACCA AMERICANA ROOT SILVER SILVER GOLD GOLD CALCIUM FLUORIDE FLUORIDE ION TRIBASIC CALCIUM PHOSPHATE CALCIUM CATION HEKLA LAVA HEKLA LAVA HYDROFLUORIC ACID FLUORIDE ION IODINE IODINE MERCURIUS SOLUBILIS MERCURIUS SOLUBILIS NICKEL NICKEL SILICON DIOXIDE SILICON DIOXIDE ZINC ZINC PLATINUM PLATINUM WATER ALCOHOL"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN: In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["PACKAGE LABEL DISPLAY: ENERGIQUE SINCE 1987 HOMEOPATHIC REMEDY DENTASTAT 1 fl. oz. (30 ml) Dentastat"]},"tags":[{"label":"Non-Standardized Food Allergenic Extract [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Active","category":"status"},{"label":"pain","category":"indication"},{"label":"minor swelling","category":"indication"},{"label":"Energique, Inc.","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"67 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"64 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"59 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"51 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"37 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"36 reports"}]},"trials":[],"aliases":[],"company":"Energique, Inc.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PLATINUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:17:54.081480+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:17:59.599555+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PLATINUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:17:59.968864+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:52.833139+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:52.833172+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:18:07.727546+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:52.833178+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:18:01.826404+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2068323/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:18:00.959163+00:00"}},"allNames":"dentastat","offLabel":[],"synonyms":["Dentastat","BERBERIS VULGARIS ROOT BARK"],"timeline":[],"approvals":[],"brandName":"Dentastat","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Non-Standardized Food Allergenic Extract [EPC]","explanation":"","oneSentence":"","technicalDetail":"As a non-standardized food allergenic extract, Dentastat likely works by activating immune cells and releasing chemical mediators that help reduce inflammation and alleviate pain."},"commercial":{},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"PLATINUM\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=platinum","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=platinum","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:39:34.633282","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:18:07.968478+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"platinum","indications":{"approved":[{"id":"platinum-pain-relief-after-dental-proce","name":"Pain relief after dental procedures","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Individuals experiencing symptoms after dental procedures","pivotalTrial":null,"restrictions":[],"patientPopulation":"Individuals experiencing symptoms after dental procedures","diagnosticRequired":null,"brandNameForIndication":"Dentastat"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07502300","phase":"PHASE3","title":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":["Extensive-stage Small-cell Lung Cancer"],"enrollment":562,"completionDate":"2029-12"},{"nctId":"NCT06996782","phase":"PHASE1,PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"enrollment":152,"completionDate":"2029-02-23"},{"nctId":"NCT07397338","phase":"PHASE1,PHASE2","title":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-01-30","conditions":["Advanced Solid Tumors","Metastatic Solid Tumors","Non-small Cell Lung Cancer (NSCLC)","NSCLC","Colorectal Cancer (CRC)","CRC"],"enrollment":370,"completionDate":"2029-05"},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":["Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8"],"enrollment":636,"completionDate":"2027-01-01"},{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":["Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma AJCC v8"],"enrollment":156,"completionDate":"2029-04-30"},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":["Stage IB Lung Non-Small Cell Carcinoma AJCC v7","Stage II Lung Non-Small Cell Cancer AJCC v7","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Cancer AJCC v8"],"enrollment":8300,"completionDate":"2026-09-28"},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":680,"completionDate":"2038-01-26"},{"nctId":"NCT04736173","phase":"PHASE2","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2021-02-08","conditions":["Non Small Cell Lung Cancer","Nonsquamous Non Small Cell Lung Cancer","Squamous Non Small Cell Lung Cancer","Lung Cancer"],"enrollment":169,"completionDate":"2027-05"},{"nctId":"NCT04633239","phase":"PHASE1","title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-02","conditions":["Recurrent Ovarian High Grade Serous Adenocarcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma"],"enrollment":42,"completionDate":"2026-11-01"},{"nctId":"NCT05198830","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-15","conditions":["Lung Adenocarcinoma","Lung Large Cell Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8"],"enrollment":42,"completionDate":"2027-06-30"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":["Bladder Urothelial Carcinoma","Muscle Invasive Bladder Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8"],"enrollment":475,"completionDate":"2027-06-01"},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":["Stage II Nasopharyngeal Carcinoma AJCC v8","Stage III Nasopharyngeal Carcinoma AJCC v8","Stage IV Nasopharyngeal Carcinoma AJCC v8"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT06589804","phase":"PHASE3","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-27","conditions":["Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Oral Cavity Squamous Cell Carcinoma","Metastatic Oropharyngeal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Neck Squamous Cell Carcinoma of Unknown Primary","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Refractory Head and Neck Squamous Cell Carcinoma","Refractory Hypopharyngeal Squamous Cell Carcinoma","Refractory Laryngeal Squamous Cell Carcinoma","Refractory Oral Cavity Squamous Cell Carcinoma","Refractory Oropharyngeal Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8"],"enrollment":158,"completionDate":"2029-11-30"},{"nctId":"NCT03473743","phase":"PHASE1,PHASE2","title":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-05","conditions":["Urothelial Carcinoma"],"enrollment":125,"completionDate":"2026-12-31"},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":["Urinary Bladder Neoplasms","Immune Checkpoint Inhibitors","Methotrexate","Vinblastine","Doxorubicin","Cisplatin","Gemcitabine"],"enrollment":150,"completionDate":"2028-10-31"},{"nctId":"NCT06050252","phase":"PHASE2","title":"Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":["Resectable Intrahepatic Cholangiocarcinoma"],"enrollment":27,"completionDate":"2027-02-12"},{"nctId":"NCT06406465","phase":"PHASE2","title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-02","conditions":["Carcinoma, Neuroendocrine","Tumor, Neuroendocrine","Tumors, Neuroendocrine","Neuroendocrine; Carcinoma","Small Cell; Receptors"],"enrollment":60,"completionDate":"2028-07-30"},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":["Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Head and Neck Carcinoma of Unknown Primary","Locally Advanced Head and Neck Squamous Cell Carcinoma","Locally Advanced Hypopharyngeal Squamous Cell Carcinoma","Locally Advanced Laryngeal Squamous Cell Carcinoma","Locally Advanced Nasal Cavity Squamous Cell Carcinoma","Locally Advanced Oral Cavity Squamous Cell Carcinoma","Locally Advanced Oropharyngeal Squamous Cell Carcinoma","Locally Advanced Paranasal Sinus Squamous Cell Carcinoma","Locally Advanced Sinonasal Squamous Cell Carcinoma","Maxillary Sinus Squamous Cell Carcinoma","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Sinonasal Cancer AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Sinonasal Cancer AJCC v8","Stage IVB Hypopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Lip and Oral Cavity Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Sinonasal Cancer AJCC v8"],"enrollment":46,"completionDate":"2026-06-01"},{"nctId":"NCT04034927","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":["Fallopian Tube Endometrioid Tumor","Fallopian Tube High Grade Serous Adenocarcinoma","Malignant Ovarian Endometrioid Tumor","Ovarian High Grade Serous Adenocarcinoma","Platinum-Sensitive Fallopian Tube Carcinoma","Platinum-Sensitive Ovarian Carcinoma","Platinum-Sensitive Primary Peritoneal Carcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian Serous Adenocarcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma"],"enrollment":61,"completionDate":"2027-02-21"},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":["Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Locally Recurrent Head and Neck Squamous Cell Carcinoma","Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma","Locally Recurrent Laryngeal Squamous Cell Carcinoma","Locally Recurrent Oral Cavity Squamous Cell Carcinoma","Locally Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage II Laryngeal Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"],"enrollment":180,"completionDate":"2033-02-01"},{"nctId":"NCT06769126","phase":"PHASE2","title":"Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-11-06","conditions":["Extensive Stage Lung Small Cell Carcinoma","Lung Small Cell Carcinoma, A Subtype","Lung Small Cell Carcinoma, I Subtype","Lung Small Cell Carcinoma, N Subtype","Lung Small Cell Carcinoma, P Subtype"],"enrollment":900,"completionDate":"2029-12-31"},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":["PRETEXT I Hepatoblastoma","PRETEXT II Hepatoblastoma","PRETEXT III Hepatoblastoma","PRETEXT IV Hepatoblastoma"],"enrollment":236,"completionDate":"2026-03-19"},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":["Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma"],"enrollment":188,"completionDate":"2029-06-30"},{"nctId":"NCT04129502","phase":"PHASE3","title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2020-01-10","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":354,"completionDate":"2026-10-31"},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":["Ganglioneuroblastoma, Nodular","Neuroblastoma"],"enrollment":478,"completionDate":"2029-12-31"},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":["Locally Advanced Cervical Adenocarcinoma","Locally Advanced Cervical Adenosquamous Carcinoma","Locally Advanced Cervical Squamous Cell Carcinoma","Stage IIIA Cervical Cancer FIGO 2018","Stage IIIB Cervical Cancer FIGO 2018","Stage IIIC1 Cervical Cancer FIGO 2018","Stage IIIC2 Cervical Cancer FIGO 2018","Stage IVA Cervical Cancer FIGO 2018"],"enrollment":336,"completionDate":"2030-12-31"},{"nctId":"NCT05019716","phase":"PHASE1,PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":["Advanced NUT Carcinoma","Metastatic NUT Carcinoma","Unresectable NUT Carcinoma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT03076554","phase":"PHASE2","title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-19","conditions":["Thymoma","Thymic Carcinoma"],"enrollment":56,"completionDate":"2027-06-30"},{"nctId":"NCT04628767","phase":"PHASE2,PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":["Renal Pelvis and Ureter Urothelial Carcinoma"],"enrollment":249,"completionDate":"2027-09-30"},{"nctId":"NCT02839707","phase":"PHASE2,PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":["Fallopian Tube High Grade Serous Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Ovarian Seromucinous Carcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Fallopian Tube Clear Cell Adenocarcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Fallopian Tube Undifferentiated Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian Undifferentiated Carcinoma","Recurrent Platinum-Resistant Fallopian Tube Carcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Clear Cell Adenocarcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal Undifferentiated Carcinoma"],"enrollment":444,"completionDate":"2026-03-31"},{"nctId":"NCT01064648","phase":"PHASE1,PHASE2","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-03-15","conditions":["Epithelioid Mesothelioma","Pleural Malignant Mesothelioma","Recurrent Malignant Mesothelioma","Sarcomatoid Mesothelioma"],"enrollment":117,"completionDate":"2026-03-19"},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":["Metastatic Malignant Solid Neoplasm","Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":55,"completionDate":"2026-12-31"},{"nctId":"NCT05815160","phase":"PHASE1","title":"Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Debiopharm International SA","startDate":"2023-05-02","conditions":["Small Cell Lung Cancer Recurrent"],"enrollment":34,"completionDate":"2026-03"},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":["Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Unresectable Urothelial Carcinoma"],"enrollment":320,"completionDate":"2028-12-31"},{"nctId":"NCT06494540","phase":"","title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-28","conditions":["Non-squamous Metastatic Non-Small-Cell Lung Carcinoma"],"enrollment":600,"completionDate":"2028-06-30"},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":["Sinonasal Squamous Cell Carcinoma","Stage III Sinonasal Cancer AJCC v8","Stage IVA Sinonasal Cancer AJCC v8","Stage IVB Sinonasal Cancer AJCC v8"],"enrollment":108,"completionDate":"2030-12-16"},{"nctId":"NCT05058651","phase":"PHASE2,PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":["Advanced Extrapulmonary Neuroendocrine Carcinoma","Metastatic Extrapulmonary Neuroendocrine Carcinoma","Recurrent Extrapulmonary Neuroendocrine Carcinoma","Unresectable Extrapulmonary Neuroendocrine Carcinoma"],"enrollment":189,"completionDate":"2028-10-01"},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":["Squamous Non-small Cell Lung Cancer"],"enrollment":180,"completionDate":"2031-05-06"},{"nctId":"NCT03952585","phase":"PHASE2,PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":["Basaloid Squamous Cell Carcinoma","Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Oropharyngeal Squamous Cell Carcinoma","Papillary Squamous Cell Carcinoma","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Squamous Cell Carcinoma"],"enrollment":384,"completionDate":"2026-12-11"},{"nctId":"NCT06008093","phase":"PHASE2","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":100,"completionDate":"2027-12-23"},{"nctId":"NCT02466971","phase":"PHASE3","title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-10","conditions":["Advanced Vaginal Adenocarcinoma","Advanced Vaginal Adenosquamous Carcinoma","Advanced Vaginal Squamous Cell Carcinoma","Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma","Stage IB2 Cervical Cancer AJCC v6 and v7","Stage II Cervical Cancer AJCC v7","Stage II Vaginal Cancer AJCC v6 and v7","Stage IIA Cervical Cancer AJCC v7","Stage IIB Cervical Cancer AJCC v6 and v7","Stage III Vaginal Cancer AJCC v6 and v7","Stage IIIB Cervical Cancer AJCC v6 and v7","Stage IV Vaginal Cancer AJCC v6 and v7","Stage IVA Cervical Cancer AJCC v6 and v7","Stage IVA Vaginal Cancer AJCC v6 and v7","Unresectable Vaginal Carcinoma","Vaginal Adenocarcinoma","Vaginal Adenosquamous Carcinoma","Vaginal Carcinoma","Vaginal Squamous Cell Carcinoma, Not Otherwise Specified"],"enrollment":450,"completionDate":"2026-07-14"},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":["Lung Non-Small Cell Carcinoma","Lung Non-Small Cell Squamous Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":1210,"completionDate":"2027-01-31"},{"nctId":"NCT05063552","phase":"PHASE2,PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":["Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Lip and Oral Cavity Carcinoma","Metastatic Nasal Cavity Squamous Cell Carcinoma","Metastatic Nasopharyngeal Squamous Cell Carcinoma","Metastatic Pharyngeal Squamous Cell Carcinoma","Metastatic Sinonasal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Nasopharyngeal Squamous Cell Carcinoma","Recurrent Pharyngeal Squamous Cell Carcinoma","Recurrent Sinonasal Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Nasopharyngeal Carcinoma AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Sinonasal Cancer AJCC v8"],"enrollment":430,"completionDate":"2027-12-15"},{"nctId":"NCT02595892","phase":"PHASE2","title":"Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-08-25","conditions":["Ovarian Serous Tumor","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma"],"enrollment":70,"completionDate":"2026-08-05"},{"nctId":"NCT01810913","phase":"PHASE2,PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":["Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma","Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7"],"enrollment":613,"completionDate":"2027-01-01"},{"nctId":"NCT04328844","phase":"PHASE1","title":"A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"iOnctura","startDate":"2020-02-25","conditions":["Solid Tumor, Adult","Non-Hodgkin Lymphoma, Adult","NSCLC","Myelofibrosis","Uveal Melanoma"],"enrollment":210,"completionDate":"2027-03"},{"nctId":"NCT02101775","phase":"PHASE2","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-21","conditions":["Ovarian Brenner Tumor","Ovarian Clear Cell Cystadenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor","Ovarian Mucinous Cystadenocarcinoma","Ovarian Seromucinous Carcinoma","Ovarian Serous Cystadenocarcinoma","Ovarian Serous Surface Papillary Adenocarcinoma","Ovarian Undifferentiated Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma"],"enrollment":124,"completionDate":"2027-03-06"},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":["Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma AJCC v8"],"enrollment":50,"completionDate":"2028-06-16"},{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":["Combined Hepatocellular Carcinoma and Cholangiocarcinoma","Stage III Liver Cancer","Stage IV Liver Cancer"],"enrollment":88,"completionDate":"2026-06-30"},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":["Endometrial High Grade Endometrioid Adenocarcinoma","Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube High Grade Serous Adenocarcinoma","Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor","Fallopian Tube Mucinous Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fallopian Tube Undifferentiated Carcinoma","FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Ovarian Seromucinous Carcinoma","Ovarian Undifferentiated Carcinoma","Platinum-Sensitive Ovarian Carcinoma","Primary Peritoneal Carcinosarcoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Primary Peritoneal Transitional Cell Carcinoma","Primary Peritoneal Undifferentiated Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma","Recurrent Ovarian Carcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian Low Grade Serous Adenocarcinoma","Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor","Recurrent Ovarian Mucinous Adenocarcinoma","Recurrent Ovarian Transitional Cell Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma"],"enrollment":54,"completionDate":"2026-06-01"},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma"],"enrollment":660,"completionDate":"2028-12-31"},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":["Non-Muscle Invasive Bladder Urothelial Carcinoma","Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma","Stage I Bladder Cancer AJCC v8"],"enrollment":160,"completionDate":"2032-02-01"},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":["Limited Stage Lung Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8"],"enrollment":544,"completionDate":"2029-02-21"},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":["Head and Neck Cancer","Head Cancer","Head Cancer Neck","Neck Cancer","Head and Neck Squamous Cell Carcinoma","HNSCC"],"enrollment":40,"completionDate":"2026-06-20"},{"nctId":"NCT04491942","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-25","conditions":["Advanced Bile Duct Carcinoma","Advanced Breast Carcinoma","Advanced Cervical Carcinoma","Advanced Endometrial Carcinoma","Advanced Esophageal Carcinoma","Advanced Gastric Carcinoma","Advanced Head and Neck Carcinoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Lung Small Cell Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Ovarian Carcinoma","Advanced Penile Carcinoma","Advanced Pleural Malignant Mesothelioma","Advanced Urothelial Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Intrahepatic Bile Duct Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Penile Cancer AJCC v8","Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Bile Duct Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Penile Cancer AJCC v8","Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8","Triple-Negative Breast Carcinoma","Unresectable Urothelial Carcinoma"],"enrollment":74,"completionDate":"2026-06-30"},{"nctId":"NCT06657144","phase":"PHASE1","title":"A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2025-04-01","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor"],"enrollment":154,"completionDate":"2028-01"},{"nctId":"NCT05092958","phase":"PHASE3","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-03","conditions":["Advanced Bladder Urothelial Carcinoma","Advanced Renal Pelvis Urothelial Carcinoma","Advanced Ureter Urothelial Carcinoma","Advanced Urethral Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8","Stage III Renal Pelvis and Ureter Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Renal Pelvis and Ureter Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8"],"enrollment":654,"completionDate":"2026-06-15"},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":["Peritoneal Mesothelioma","Peritoneal Carcinomatosis","Ovarian Cancer","Gastrointestinal Cancer","Appendiceal Cancer","Atypical Mesothelial Proliferation","Colorectal Cancer"],"enrollment":60,"completionDate":"2034-12-30"},{"nctId":"NCT05691478","phase":"PHASE2,PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":["High Grade Osteosarcoma","Localized Osteosarcoma","Metastatic Osteosarcoma","Secondary Osteosarcoma"],"enrollment":1122,"completionDate":"2030-03-20"},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":["Gynecologic Cancers","Platinum-Sensitive Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer (PSOC)"],"enrollment":377,"completionDate":"2028-02"},{"nctId":"NCT02535312","phase":"PHASE1,PHASE2","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-08","conditions":["Advanced Malignant Solid Neoplasm","Advanced Peritoneal Malignant Mesothelioma","Advanced Pleural Malignant Mesothelioma","Recurrent Peritoneal Malignant Mesothelioma","Recurrent Pleural Malignant Mesothelioma","Refractory Malignant Solid Neoplasm","Unresectable Solid Neoplasm"],"enrollment":30,"completionDate":"2026-10-15"},{"nctId":"NCT05578326","phase":"PHASE2","title":"Study of Trilaciclib and Lurbinectidin","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-10-12","conditions":["Lung Cancer","Small-cell Lung Cancer"],"enrollment":30,"completionDate":"2028-12-25"},{"nctId":"NCT06694454","phase":"PHASE1,PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-02","conditions":["Non-small Cell Lung Cancer (NSCLC)","Carcinoma, Non-Small Cell Lung","Non-Small Cell Lung Carcinoma","Non Small Cell Lung Cancer","Non Small Cell Lung Carcinoma"],"enrollment":60,"completionDate":"2034-12-31"},{"nctId":"NCT07284121","phase":"","title":"A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-17","conditions":["Lung Cancer, Hepatocellular Carcinoma"],"enrollment":700,"completionDate":"2028-12-31"},{"nctId":"NCT06439225","phase":"PHASE3","title":"Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-12-30","conditions":["Metastatic Castration-resistant Prostate Cancer","Metastatic Prostate Cancer"],"enrollment":236,"completionDate":"2030-03-31"},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":["Advanced or Metastatic Solid Tumors"],"enrollment":72,"completionDate":"2026-05-19"},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":["Lymphoma"],"enrollment":129,"completionDate":"2026-12-31"},{"nctId":"NCT07149649","phase":"PHASE2,PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":["Metastatic NSCLC - Non-Small Cell Lung Cancer"],"enrollment":230,"completionDate":"2035-03-31"},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":["Non-squamous Non-small Cell Lung Cancer"],"enrollment":878,"completionDate":"2030-03-25"},{"nctId":"NCT07361497","phase":"PHASE3","title":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-16","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":850,"completionDate":"2033-12-31"},{"nctId":"NCT07497074","phase":"PHASE2","title":"JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2026-04","conditions":["Cervical Cancer"],"enrollment":78,"completionDate":"2028-06"},{"nctId":"NCT06223568","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-10","conditions":["Squamous Cell Carcinoma of the Head and Neck","Oropharynx","Human Papillomavirus Viruses","Drug Therapy","Cancer Vaccine"],"enrollment":70,"completionDate":"2028-01-10"},{"nctId":"NCT06953323","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":["Advanced Solid Tumor"],"enrollment":86,"completionDate":"2029-12-30"},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":["Non Small Cell Lung Cancer"],"enrollment":780,"completionDate":"2034-10-23"},{"nctId":"NCT07495384","phase":"NA","title":"Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-01-17","conditions":["Recurrent Ovarian Cancer","Platinum Resistance"],"enrollment":40,"completionDate":"2029-11-01"},{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":["Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Metastatic","Ovarian Cancer Metastatic Recurrent","Non-squamous EGFR Wt NSCLC","Platinum Resistant Ovarian Cancer","PROC"],"enrollment":226,"completionDate":"2028-12"},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":["Small Cell Lung Cancer Limited Stage"],"enrollment":100,"completionDate":"2029-07-31"},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":520,"completionDate":"2030-06-14"},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":["Ovarian Neoplasms","Ovarian Cancer"],"enrollment":900,"completionDate":"2033-02-25"},{"nctId":"NCT07276360","phase":"PHASE2","title":"Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","status":"RECRUITING","sponsor":"Uganda Cancer Institute","startDate":"2026-03-11","conditions":["Cervical Cancer","Cervix Cancer","Cervical Adenocarcinoma","Cervical Small Cell Carcinoma","Cervical Adenosquamous Carcinoma"],"enrollment":278,"completionDate":"2029-01-02"},{"nctId":"NCT07497607","phase":"PHASE2","title":"Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sara Medek","startDate":"2026-06-01","conditions":["Oropharyngeal Squamous Cell Carcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma"],"enrollment":31,"completionDate":"2036-06-01"},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"enrollment":770,"completionDate":"2032-11-09"},{"nctId":"NCT05657873","phase":"PHASE2","title":"A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-12-09","conditions":["Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non-small Cell Carcinoma","NSCLC","NSCLC Stage IV"],"enrollment":68,"completionDate":"2026-12-09"},{"nctId":"NCT06843447","phase":"PHASE1,PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":["Ovarian Cancer Recurrent"],"enrollment":280,"completionDate":"2029-03-27"},{"nctId":"NCT07489287","phase":"PHASE1","title":"GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-06-15","conditions":["Platinum-resistant Ovarian Cancer"],"enrollment":18,"completionDate":"2030-01-15"},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor","Non-small Cell Lung Cancer","SMARCA4-Deficient Tumor"],"enrollment":340,"completionDate":"2027-10"},{"nctId":"NCT06225596","phase":"PHASE2,PHASE3","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","status":"RECRUITING","sponsor":"BicycleTx Limited","startDate":"2024-01-24","conditions":["Metastatic Urothelial Cancer"],"enrollment":956,"completionDate":"2030-12"},{"nctId":"NCT07498959","phase":"NA","title":"Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2026-03-19","conditions":["Testicular Cancer","Seminoma","Quality of Life","De-escalation","RPLND"],"enrollment":160,"completionDate":"2032-03-25"},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":["Advanced Biliary Tract Carcinoma"],"enrollment":75,"completionDate":"2029-11"},{"nctId":"NCT06538038","phase":"","title":"Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients","status":"RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2024-09-17","conditions":["Non Small Cell Lung Cancer","Epidermal Growth Factor Receptor Gene Mutation","Stage III Lung Cancer","Stage IV Lung Cancer"],"enrollment":538,"completionDate":"2029-08"},{"nctId":"NCT07495098","phase":"PHASE1","title":"Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-07-01","conditions":["Lung Cancer Metastatic","Lung Cancer (NSCLC)"],"enrollment":12,"completionDate":"2031-06-30"},{"nctId":"NCT01846390","phase":"PHASE1","title":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2013-10-01","conditions":["Peripheral T-Cell Lymphoma","Diffuse Large B-Cell Lymphoma"],"enrollment":21,"completionDate":"2018-09-19"},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":["Carcinoma, Non-Small-Cell Lung","Neoplasm Metastasis"],"enrollment":1264,"completionDate":"2031-01"},{"nctId":"NCT06123754","phase":"PHASE3","title":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2023-11-17","conditions":["Non-small Cell Lung Cancer"],"enrollment":390,"completionDate":"2027-12-30"},{"nctId":"NCT05555732","phase":"PHASE3","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-01-11","conditions":["Metastatic Non Small Cell Lung Cancer"],"enrollment":1170,"completionDate":"2029-05-11"},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":["Resectable NSCLC","KRAS G12C Mutation","Stage IB-IIIA NSCLC","Neoadjuvant Therapy"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT06992609","phase":"PHASE3","title":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-15","conditions":["Small Cell Lung Carcinoma"],"enrollment":70,"completionDate":"2029-06-30"},{"nctId":"NCT07138755","phase":"PHASE2","title":"The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-29","conditions":["NSCLC","Sintilimab","Adaptive Radiotherapy"],"enrollment":35,"completionDate":"2030-09"},{"nctId":"NCT04919512","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-07","conditions":["Urinary Bladder Neoplasms"],"enrollment":163,"completionDate":"2026-03-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"UNII":"1TH8Q20J0U","SPL_ID":"1f92ea6e-90d0-427d-a07f-ac1a41600d5a","chemblId":"CHEMBL2068323"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Energique, Inc.","relationship":"Original Developer"}],"publicationCount":62072,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Energique, Inc.","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Energique, Inc.","companyId":"energique-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:18:07.968478+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}